Plaintiff-appellant Peter S. Bernard appeals from a summary judgment entered on September 30, 1991 in the United States District Court for the Eastern District of New York (Wexler,
J.)
in favor of defendants-appellees Commerce Drug, Inc. (“Commerce”) and parent-company Del Laboratories, Inc. In bringing this action to seсure damages and injunctive relief, Bernard alleged,
inter alia,
that defen
*1339
dants’ “ArthriCare” trademark infringed his “Arthriticare” mark in violation of the Lanham Act, 15 U.S.C. § 1125(a). The district court granted defendants’ motion for summary judgment and dismissed plaintiff’s infringement claim, holding that Arthriticare is a descriptive trademark, that the mark had not acquired secondary meaning, and that the mark therefore was not entitled to trademark protection.
Bernard v. Commerce Drug Co.,
BACKGROUND
In August 1989, Bernard, doing business as TBG Marketing Company, conducted a trademark search for “Arthriticare”, a name he intended to use to market a topical heat analgesic designed to provide relief for arthritis sufferers. His product is a gel that is applied to the surface of the user’s skin. The area of skin where the gel is applied then is immersed in warm water until the user is relieved of arthritis pain. Pursuant to a licensing arrangement, Bernard was given an option, to expire October 31, 1990, to become a formаl licensee with marketing rights to the product. Bernard’s trademark search revealed no conflicting uses and thereafter, on December 1, 1989, he filed an application for federal trademark registration with the Patent and Trademark Office.
Thirteen days after Bernard’s application was filed, Commerсe filed a trademark application for the name “ArthriCare.” Commerce, a major over-the-counter pharmaceutical manufacturer, had been for many years marketing a topical analgesic, functionally similar to Bernard’s, under the trademark Exocaine. For marketing reasons, Commerce desired to change the name of its product to ArthriCare. After a September 1989 trademark search revealed no conflicting trademarks, Commerce filed its trademark application. In March 1990, the Patent and Trademark Office notified Commerce that its ArthriCare trademark application would be suspended pending disposition of Bernard’s Arthriticare trademark application.
Bernard had begun marketing efforts for his Arthriticare product through direct mailings in February 1990. He mailed approximately 20,000 offers for free samples to targeted potential customers. Eight thousand of those targeted responded by requesting samples, and 240 of the target group eventually ordered and paid for the product — the first sale occurring on or about April 1, 1990. Subsequently, Bernard allowed the licensing option for the Arthriticare product to expire by not exercising his licensing agreement option rights before the end of Oсtober 1990 (although he contends that he continues to sell the product from inventory produced under the licensing agreement). In contrast, Commerce began marketing its ArthriCare product in June 1990 through national retail stores, and has sold over 800,000 units. Commerce aggressively continues to market its ArthriCare product.
In an оpposition to Bernard’s attempted trademark registration dated August 7, 1990 and filed with the Patent and Trademark Office, Commerce alleged that it “commenced to use and has continued to use the trademark Arthricare” prior to the time Bernard filed his trademark application. As a second ground of oрposition, Commerce asserted that “[s]ince the word ‘arthritic’ is both an adjective and a noun, the purported trademark Arthriticare is no more than a descriptive combination word describing care for a person afflicted with arthritis and, accordingly, is unregistrable under Section 2(e) of the Lanham Act bеcause when used in connection with [Bernard’s] goods the word is merely descriptive of them.” On February 27, 1991, Commerce withdrew its first ground of opposition to Bernard’s trademark application that alleged prior use, conceding that its only prior use was “token use” “not conferring] any right of priority on [Commerce].” Cоmmerce continued, however, to maintain that Bernard’s trademark was descriptive, and therefore “unregistrable.”
On March 27, 1991, Bernard commenced this suit against Commerce alleging: (i) trademark infringement pursuant to 15 U.S.C. § 1125(a); (ii) false or fraudulent *1340 trademark registration under 15 U.S.C. § 1120; and (iii) various state and common law claims. By noticе of motion dated May 21, 1991, Commerce moved for summary judgment on the section 1125(a) infringement count, for judgment on the pleadings for failure to state a claim on the section 1120 fraudulent registration count, and for dismissal for lack of subject matter jurisdiction on the remaining state and common law claims. On June 10, 1991, Bernard filed а cross-motion for summary judgment on the trademark infringement claim, maintaining that his Arthriticare trademark was a suggestive mark, and that Commerce’s use of a virtually identical trademark constituted infringement. By order dated September 27, 1991, the district court granted summary judgment for Commerce on the infringement claim, granted judgment on the pleadings for failure to state a fraudulent registration claim, and dismissed the remaining state and common law claims for lack of subject matter jurisdiction. Bernard now appeals, arguing that the district court erred by granting summary judgment in favor of Commerce on the infringement claim.
DISCUSSION
A moving party is entitled to summary judgment upon a shоwing “that there is no genuine issue as to any material fact and that the moving party is entitled to a judgment as a matter of law.” Fed.R.Civ.P. 56(c). We review a district court’s grant of summary judgment
de novo. Citizens Bank of Clearwater v. Hunt,
The law of trademarks identifies four categories of terms with respect to trademark protection. “Arrayed in an ascending order which rоughly reflects their eligibility to trademark status and the degree of protection accorded, these classes are (1) generic, (2) descriptive, (3) suggestive, and (4) arbitrary or fanciful.”
Abercrombie & Fitch Co. v. Hunting World, Inc.,
In the instant case, the district court concluded that Arthriticare, as applied to an analgesic gel formulated to relieve arthritis pain, is a descriptive trademark.
Bernard,
On appeal, Bernard argues that the district court erred in concluding that Arthriticare is a descriptive trademark because “it necessarily requires the exercise of sоme thought, perception or imagination to conjure the image of a pain relieving topical analgesic gel from the coined word.” Commerce counters that the court properly found Bernard’s mark to be descriptive, as “no imagination is necessary for the public to understand that ‘Arthriticare’ is a product intended for the care of arthritics or treatment of arthritis.” For the reasons stated below, we agree with the district court’s conclusion that Arthriticare is a descriptive trademark and affirm the judgment of that court.
While we have identified and employed useful standards to guide our analysis as to whеther a term is descriptive or suggestive,
see generally Papercutter,
We consistently have utilized the following formulation to distinguish between terms that arе descriptive and those that are suggestive:
A term is suggestive if it requires imagination, thought and perception to reach a conclusion as to the nature of goods. A term is descriptive if it forthwith conveys an immediate idea of the ingredients, qualities or characteristics of the goods.
Abercrombie & Fitch,
, Applying these рrinciples, we are constrained to agree with the district court’s conclusion that Arthriticare is a descriptive trademark in the context here presented. Clearly, the mark describes the problem or condition (arthritis) that the trademarked product is designed to remedy or otherwise deal with.
See 20th Century Wear,
The conclusion that Arthriticare, as applied to an arthritis rub, is a descriptive term is supportеd by case law.
See Papercutter,
As noted, we previously have held that “Sportscreme”, also a topical analgesic rub, wаs a descriptive trademark because “[n]o exercise of the imagination is necessary for the public to understand that the product is a cream useful in connection with sports.”
Thompson Medical,
Our conclusion is bolstered by the conсern that “exclusive use of the term might unfairly ‘monopolize’ common speech,”
20th Century Wear,
Bernard primarily relies on our decisions in
Hasbro, Inc., v. Lanard Toys, Ltd.,
In
Physicians Formula,
we held that the mark “Physicians Formula,” for skin care products, was suggestive “because the mark does little to identify the product other than to locate it in the realm of medicine.”
Physicians Formula,
Also inapposite is our decision in
West & Co.,
We also agree with the district court, for the reasons stated in its memorandum and order,
We have considered appellant’s remaining arguments and find them to be without merit.
CONCLUSION
For the reasons stated, we affirm the judgment of the district court.
